Top video innovator names Keith Budge as vice president, Asia Pacific and Japan;
releases new data on multiscreen video trends in Asia-Pacific countries

WATERTOWN, Mass. – June 18, 2013 – FORMA Therapeutics announced today its Asset Discovery
and Development Company (“ADDCo”) platform, an initiative in which FORMA will join forces with select
academic, not-for-profit and venture philanthropy institutions to transform basic research discoveries into
life-saving therapies.

SYDNEY, AUSTRALIA AND EMERYVILLE, CALIF., JUNE 18, 2013 – Adamas Pharmaceuticals,
Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl extended
release) capsules demonstrating a statistically significant improvement in levodopa-induced dyskinesia
(LID) as measured by change from baseline at week 8 versus placebo in the Unified Dyskinesia Rating
Scale (UDysRS).

Report identifies RAMP among five vendors offering innovations around content and structured
data

Osaka, Japan, May 8, 2013, Deerfield, IL and Fort Collins, CO, U.S.A., May 7, 2013 – Takeda
Pharmaceutical Company Limited (“Takeda”) and Inviragen, Inc. (“Inviragen”) jointly announced today that
Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a
definitive agreement for Takeda to acquire Inviragen for an upfront payment of US$35 million, and future
payments of up to US$215 million linked to the progress of clinical development and achievement of key
commercial milestones.

PLEASANTON, Calif. and SINGAPORE, March 26, 2013 /PRNewswire/ — TriReme Medical, Inc. and its
affiliates (TriReme) announced today that it has signed a comprehensive agreement with Weihai Weigao
Medical Devices, Ltd for the distribution of its products in the People’s Republic of China. Weigao will act
as TriReme’s master distributor by selling TriReme products directly to hospitals as well as connecting
TriReme products into its vast nationwide distribution network. This agreement complements TriReme’s
strategy of focusing on Asia, the fastest growing market in interventional cardiology.

FORT COLLINS, Colo. – FEBRUARY 27, 2013 – Inviragen, Inc. today announced the initiation of the
second stage of an ongoing Phase 2, randomized, double-blind, placebo-controlled study of DENVax™,
the Company’s investigational dengue vaccine.

Huge and scary numbers accompany the costs of drug development, including a study last year
in Forbes that averaged the total spending per new med from several top pharma groups at $4
billion. Yikes. Behind that big figure is a litany of various holes and dysfunctional practices in the
process of bringing a new drug to market.

The Board of Directors of Ezion Holdings Limited (the “Company” or “Group”) is pleased to
announce that the Group has been awarded a letter of intent from a South East Asian Statelinked corporation for the charter of one unit of Liftboat over a 4 year period with an approximate
contract value of up to US$ 116.8 million.

One of the main things content providers can do to create rich user experiences is present
contextualized content that relates to the underlying article or video. This is why so many
content sites have “Read More,” “You Might Also Enjoy” and “Also View” type sections. They
help content providers increase users’ time spent (which drives monetization), build loyalty
and create competitive barriers